15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $37M | -$8M | 71.5% | -39.8% | -$13M | $17M | $6M |
| 2024 | $36M | -$21M | 69.9% | -46.2% | -$15M | $14M | $3M |
| 2023 | $31M | -$29M | 70.6% | -102.8% | -$22M | $5M | $14M |
| 2022 | $35M | -$33M | 59.8% | -90.9% | -$34M | $5M | $22M |
| 2021 | $43M | -$25M | 74.4% | -52.7% | -$18M | — | $52M |
| 2020 | $41M | -$8M | 73.0% | -25.3% | -$6M | $0 | $71M |
| 2019 | $25M | -$19M | 70.5% | -76.0% | -$17M | $15M | $12M |
| 2018 | $23M | -$17M | 66.7% | -69.3% | -$12M | $10M | $22M |
| 2017 | $15M | -$8M | 63.6% | -65.0% | -$7M | $10M | $17M |
| 2016 | $8M | -$12M | 67.9% | -140.0% | -$7M | $5M | $5M |
| 2015 | — | -$9M | — | — | -$9M | $0 | $5M |
| 2014 | — | -$9M | — | — | -$7M | — | $4M |
| 2014 | — | -$95M | — | — | -$74M | — | $5M |
| 2014 | — | -$93M | — | — | -$73M | — | $6M |
| 2013 | — | -$5M | — | — | -$4M | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $9M | -$5M | 69.2% | -34.3% | -$1M | $17M | $5M |
| Dec '25 | $9M | -$5M | 73.7% | -47.5% | -$5M | $17M | $6M |
| Sep '25 | $9M | -$3M | 70.3% | -30.2% | -$3M | $15M | $8M |
| Jun '25 | $10M | $2M | 70.9% | -37.6% | -$2M | $14M | $10M |
| Mar '25 | $9M | -$1M | 71.1% | -44.6% | -$3M | $14M | $12M |
| Dec '24 | $9M | -$8M | 68.4% | -37.1% | -$2M | $14M | $3M |
| Sep '24 | $9M | -$3M | 61.0% | -56.1% | -$3M | $14M | $6M |
| Jun '24 | $9M | -$4M | 73.5% | -40.4% | -$5M | $14M | $8M |
| Mar '24 | $9M | -$6M | 76.5% | -51.8% | -$5M | $4M | $9M |
| Dec '23 | $3M | -$7M | 143.1% | -296.2% | -$7M | $5M | $14M |
| Sep '23 | $9M | -$9M | 63.6% | -83.4% | -$5M | $5M | $8M |
| Jun '23 | $9M | -$6M | 63.9% | -69.6% | -$7M | $5M | $13M |
| Mar '23 | $9M | -$7M | 57.7% | -83.5% | -$4M | $5M | $19M |
| Dec '22 | $9M | -$766126 | 61.3% | -67.7% | -$6M | $5M | $22M |
| Sep '22 | $8M | -$12M | 44.6% | -111.2% | -$7M | — | $23M |
| Jun '22 | $8M | -$11M | 58.2% | -98.4% | -$13M | — | $30M |
| Mar '22 | $9M | -$9M | 73.8% | -89.6% | -$9M | — | $43M |
| Dec '21 | $11M | -$9M | 71.0% | -88.7% | -$7M | — | $52M |
| Sep '21 | $10M | -$6M | 74.8% | -55.4% | -$5M | — | $61M |
| Jun '21 | $12M | -$5M | 77.5% | -41.0% | -$3M | — | $66M |
How the market has priced CTSO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cytosorbents Corp's revenue has declined 2.0% per year. These are computed facts, not advice.
As of FY2025, Cytosorbents Corp reported $17M of total debt against $6M of cash.
In FY2025, gross margin was 71.5%, operating margin -39.8%, and net margin -22.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.